Drug Profile


Alternative Names: 2118436; B-RafV600E inhibitor; DRB 436; GSK 2118436A; GSK-2118436; Tafinlar

Latest Information Update: 12 Jun 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Novartis; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides; Thiazoles
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Registered Non-small cell lung cancer
  • Phase II Brain metastases; Cancer
  • Phase I/II Colorectal cancer; Solid tumours

Most Recent Events

  • 04 Jun 2017 Efficacy and adverse event data from the phase II COMBI-MB trial in Malignant melanoma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 03 Apr 2017 Registered for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) in European Union, Norway, Iceland, Liechtenstein (PO)
  • 23 Feb 2017 CHMP recommends approval of trametinib in combination with dabrafenib for Non-small cell lung cancer (Combination therapy, Late-stage, Metastatic disease) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top